AI-generated · cited to primary sources · not investment advice
Senores Pharma. (544319) Nov 2025 Filing Analysis
How durable is the business?
The transcript describes an API facility under development, intended mainly to supply ingredients for Senores' own medicines and strengthen supply security. Management estimated Rs. 50–100 Cr of potential facility revenue after approval, while stressing that internal use and supply-chain protection are the main purposes. The later baseline reports Rs. 6.8 Cr for Others, including API sales, but does not isolate API revenue. Because the transcript does not provide a comparable current API-sales figure, a segment revenue change cannot be calculated; the specific backward-integration initiative is an earlier strategic development. (1 new)
“The targeted revenue should be between INR50 and INR100 crores from that facility for the next year. ... the products that we currently have will be largely used for backward integration for supply chain protection.”
See the full cited Business Model analysis of Senores Pharma.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.